C.R. Bard, Inc. (NYSE:BCR) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $11.70-$11.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.81.

C.R. Bard, Inc. (NYSE BCR) traded up 0.07% on Thursday, hitting $321.41. The stock had a trading volume of 980,221 shares. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The firm’s 50 day moving average price is $317.17 and its 200-day moving average price is $276.63. The stock has a market cap of $23.28 billion, a PE ratio of 40.91 and a beta of 0.59.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Monday, July 24th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 15.70% and a return on equity of 48.72%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.54 EPS. On average, analysts forecast that C.R. Bard, Inc. will post $11.78 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be issued a $0.26 dividend. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.32%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.21%.

Several analysts recently weighed in on the stock. BidaskClub downgraded shares of C.R. Bard from a strong-buy rating to a buy rating in a report on Wednesday, July 19th. Zacks Investment Research downgraded shares of C.R. Bard from a buy rating to a hold rating in a research note on Monday, July 17th. BMO Capital Markets restated a hold rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. Finally, Raymond James Financial, Inc. downgraded shares of C.R. Bard from a strong-buy rating to a mkt perform rating in a research note on Wednesday, April 26th. Eleven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $271.31.

WARNING: “C.R. Bard, Inc. (NYSE:BCR) Updates FY17 Earnings Guidance” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/27/c-r-bard-inc-nysebcr-updates-fy17-earnings-guidance.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Earnings History and Estimates for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.